GET DAILY SIGNALSCardiol Therapeutics (CRDL) Analyst Targets Point to +680% Upside from Current Levels
Key Takeaways
- The central price target stands at $8.75, the arithmetic mean of four current analyst estimates.
- With the latest verified price near $1.12, reaching that level would require an increase of roughly 680% — a substantial move for any equity.
- Individual targets range widely from $5.00 to $11.00, highlighting differing views on clinical prospects.
- The bull case centers on Cardiol Therapeutics (CRDL) advancing CardiolRx through late-stage trials for rare heart conditions.
- Key risks include the company’s pre-revenue status, ongoing cash burn, and reliance on binary trial results.
- Additional details are available on the Major News, Today's Price Move, Forecast, and Earnings pages.
Analyst Consensus and Price Targets
Cardiol Therapeutics Inc. (CRDL) is a clinical-stage biotech firm headquartered in Oakville, Canada, focused on anti-inflammatory and anti-fibrotic treatments for cardiac disease. Its lead asset, CardiolRx, is an oral CBD formulation under investigation for uncommon heart conditions.
Four attributable analyst targets were examined. B. Riley Securities (Mayank Mamtani) opened coverage with a Buy rating and $11.00 target in August 2026. Canaccord Genuity (Edward Nash) maintained a Buy and lifted its target to $10.00. H.C. Wainwright (Brandon Folkes) kept a Buy with a $9.00 target. Brookline Capital (Fozia Ahmed) maintains a Buy at $5.00. The simple average of these four figures is $8.75, spanning $5.00 to $11.00.
The broad dispersion reflects fundamental uncertainty in valuing a pre-revenue company whose prospects hinge on clinical data. Higher targets assume meaningful commercial success for CardiolRx, while the lower one incorporates greater caution around dilution and execution. This average is not an official consensus and should not be treated as a guaranteed outcome.
Current Price Level and the Path to the Target
Trading near $1.12, the stock would need to climb approximately 680% to hit the $8.75 midpoint. That magnitude exceeds what most large-cap equities achieve in a typical year. Shares remain well below the 52-week high of roughly $2.34, and even a return to that level would leave them far short of the average target.
Any move higher would likely be driven by clinical catalysts rather than steady earnings growth. Positive data from the Phase III MAVERIC trial in recurrent pericarditis, where CardiolRx carries FDA Orphan Drug Designation, could prompt a meaningful re-rating by moving the company closer to potential approval and revenue. Analyst targets for clinical-stage companies often embed scenario-weighted probabilities rather than linear forecasts.
Factors That Could Support Progress Toward the Target
- Late-stage development: CardiolRx is in the pivotal Phase III MAVERIC trial for recurrent pericarditis and has finished the Phase II ARCHER study in acute myocarditis.
- Regulatory advantages: Orphan Drug Designation offers potential market exclusivity and development benefits upon approval.
- Expanded pipeline: CRD-38, a subcutaneous CBD candidate aimed at heart failure, adds longer-term optionality.
- Analyst momentum: Recent coverage has been constructive, with Canaccord raising its target and B. Riley initiating with a Buy.
Risks That Could Keep the Target Out of Reach
- Clinical uncertainty: Late-stage trials often fail, and a negative MAVERIC readout would likely weigh heavily on valuation.
- Absence of revenue: CRDL has no product sales and finances operations through equity raises, leading to potential ongoing dilution.
- Cash consumption: Operating losses continue, and analysts project a full-year loss per share for the current fiscal year.
- Valuation challenges: Without earnings, the share price rests almost entirely on forward-looking assumptions.
Technical Framework and Price Structure
The 52-week range of approximately $0.88 to $2.34 sets the broader context. The $2.34 high represents a notable resistance area, while $0.88 serves as key support. At current levels near $1.12, the stock sits in the lower half of that band, and any sustained advance toward the average target would first need to clear the prior high.
Key Events and Time Horizon to Watch
Analyst targets generally look out about 12 months. For CRDL the critical catalysts are clinical and regulatory milestones rather than quarterly results. Investors should track progress on the Phase III MAVERIC trial, enrollment updates, FDA interactions, and any financing moves that affect cash runway. Cash position and burn rate remain important secondary considerations.
Monitoring Market Signals with AI Tools
I also checked this using Tickeron’s AI Daily Buy/Sell Signals to see how the stock compares to others in the industry. For a catalyst-driven name like CRDL, automated trend monitoring can help identify shifts more efficiently than manual tracking alone.
Using Tickeron AI Daily Buy/Sell Signals in Practice
Tickeron’s AI Daily Buy/Sell Signals applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on evolving market conditions and technical patterns. For volatile, event-driven equities such as CRDL, these data-driven signals can complement independent research and help track position changes more systematically. I find the tool helpful when reviewing multiple names alongside my own analysis of clinical milestones and cash metrics.
Overall Perspective
Achieving the $8.75 average target would require CRDL to advance roughly 680% from near $1.12, an outcome that hinges almost entirely on clinical success. The constructive case rests on positive MAVERIC data and eventual approval of CardiolRx, while the cautious view centers on trial setbacks, continued dilution, and lack of revenue. The wide $5.00–$11.00 range illustrates how divided opinions remain on a pre-revenue biotech. The central target is best viewed as a scenario-weighted average rather than a precise prediction, so attention should stay on trial progress, cash runway, and financing developments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CRDL's RSI Indicator is staying in oversold zone for 18 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 66 of 72 cases where CRDL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for CRDL just turned positive on October 23, 2026. Looking at past instances where CRDL's MACD turned positive, the stock continued to rise in 43 of 49 cases over the following month. The odds of a continued upward trend are 88%.
Following a +6.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRDL advanced for three days, in 178 of 220 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
CRDL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
CRDL moved below its 50-day moving average on September 28, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CRDL crossed bearishly below the 50-day moving average on October 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRDL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for CRDL entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.765) is normal, around the industry mean (8.432). P/E Ratio (-3.353) is within average values for comparable stocks, (-1.821). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. CRDL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRDL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric
Advertisement